Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw a downside of -0.29% to close Monday at $10.38 after subtracting -$0.03 on the day. The 5-day average trading volume is 10,408,880 shares of the company’s common stock. It has gained $11.24 in the past week and touched a new high 1 time within the past 5 days. An average of 10,522,225 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 9,725,408.
TEVA’s 1-month performance is 19.45% or $1.14 on its low of $9.00 reached on 12/30/22. The company’s shares have touched a 52-week low of $6.78 and high of $11.44, with the stock’s rally to the 52-week high happening on 01/12/23. YTD, TEVA has achieved 13.82% or $1.26 and has reached a new high 5 times. However, the current price is down -9.31% from the 52-week high price.
TEVA stock investors last saw insider trading activity on Aug 22.Kalif Eliyahu Sharon (EVP, Chief Financial Officer) most recently sold 55,500 shares at $10.07 per share on Aug 22. This transaction cost the insider $558,696. Exec. VP Chief Legal Officer, Stark David Matthew, sold 58,163 shares at a price of $9.04 on Jul 28. Then, on May 17, Executive VP, Global R&D Fridriksdottir Hafrun sold 130,000 shares at a price of $8.22 per share. This transaction amounted to $1,068,067.
TEVA stock has a beta of 1.20. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.76 while the price-to-book (PB) in the most recent quarter is 1.32, with the price to cash flow ratio at 22.48.
Teva Pharmaceutical Industries Limited’s quick ratio for the period ended September 29 was 0.70, with the current ratio over the same period at 1.00. As well, the company’s long term debt to equity for the quarter ending September 29 was 2.11, while the total debt to equity was 2.43. In terms of profitability, the gross margin trailing 12 months is 49.30%. The trailing 12-month EBITDA margin is 27.75% while for the period ending September 29, Teva Pharmaceutical Industries Limited’s operating margin was -7.70%. The firm’s gross profit as reported stood at $7.59 billion against revenue of $15.88 billion.
For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -421.43% to $56.0 million, while revenue of -$232.0 million was 514.29% off the previous quarter. Analysts expected TEVA to announce $0.62 per share in earnings in its latest quarter, but it posted $0.59, representing a -4.80% surprise. EBITDA for the quarter stood at more than $764.0 million. TEVA stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 34.73 billion, with total debt at $21.62 billion. Shareholders hold equity totaling $1.11 billion.
Let’s look briefly at Teva Pharmaceutical Industries Limited (TEVA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 50.54% to suggest the stock is trending Neutral, with historical volatility in this time period at 42.06%.
The stock’s 5-day moving average is $10.64, reflecting a -7.65% or -$0.86 change from its current price. TEVA is currently trading +17.02% above its 20-day SMA, +10.43% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +14.32% and SMA200 by+4.11%.
Stochastic %K and %D was 58.01% and 65.74% and the average true range (ATR) pointed at 0.37. The RSI (14) points at 56.45%, while the 14-day stochastic is at 52.98% with the period’s ATR at 0.36. The stock’s 9-day MACD Oscillator is pointing at -0.44 and -0.19 on the 14-day charts.
In the most recent analyst report for Teva Pharmaceutical Industries Limited (NYSE: TEVA), Jefferies downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for TEVA stock have a consensus rating for the stock as Hold. Currently, 3 brokerage advisors rate TEVA as a “sell,”, while 7 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 2 have offered a “buy” rating.
What is TEVA’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $13.00, with their median price target at $10.00. Looking at these predictions, the average price target given by analysts is for Teva Pharmaceutical Industries Limited (TEVA) stock is $10.11.